库存0件
axolGEM iPSC-Derived Neural Stem Cells LRRK2 G2019S HOM (1.5 million cells) and Neural Plating-XF Medium (30 mL)
Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is heterozygous for the G2019S mutation where one allele contains the mutation and the other allele is wild type at the locus. Click on the product images to see the data and further details.
The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Starting material
Dermal fibroblast
Donor gender
Female
Donor age at sampling
64 yrs
Karyotype
Normal
Reprogramming method
Episomal vector
Induction method
Monolayer & chemically defined medium
Genetic modification
Heterozygous for the LRRK2 G2019S mutation (GGC>AGC)
Genetic modification
Contains a puromycin resistance cassette (intronic)
Size
≥1.5 million cells
Kit components
1 vial of axolGEM Neural Stem Cells (≥1.5 million cells) and 1 bottle of Plating-XF Medium (30 mL)
Growth properties
Adherent
Shipping conditions
Dry ice
Storage conditions
Liquid nitrogen